Basilea Pharmaceutica (XSWX:BSLN) ROCE %

: -22.18% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Basilea Pharmaceutica's annualized ROCE % for the quarter that ended in Dec. 2023 was -22.18%.

Basilea Pharmaceutica ROCE % Historical Data

The historical data trend for Basilea Pharmaceutica's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-8.84

-4.35

1.07

20.06

15.95

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %																26.08	-21.90	53.57	48.78	-22.18

Basilea Pharmaceutica ROCE % Calculation

Basilea Pharmaceutica's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	21.663	/	( ( (220.848 - 74.85)	+	(173.289 - 47.592) )	/ 2 )
	=	21.663	/	( (145.998	+	125.697)	/ 2 )
	=	21.663	/	135.8475
	=	15.95 %

Basilea Pharmaceutica's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-32.002	/	( ( (230.034 - 67.185)	+	(173.289 - 47.592) )	/ 2 )
	=	-32.002	/	( ( 162.849	+	125.697 )	/ 2 )
	=	-32.002	/	144.273
	=	-22.18 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Basilea Pharmaceutica (XSWX:BSLN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Basilea Pharmaceutica ROCE % Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (XSWX:BSLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BSLNz:UK

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (XSWX:BSLN) Headlines

No Headlines